Table 2. Test for the difference of the hypothyroidism reporting rate between sunitinib and sorafenib in the FDA adverse event reporting system (FAERS).
Sunitinib | Sorafenib | |
---|---|---|
Hypothyroidism Reported | 287 | 55 |
Hypothyroidism Not Reported | 16955 | 9579 |
Ratio of Hypothyroidism Report (%) | 1.66 | 0.57 |
Odds Ratio (95% CI) | 2.95 (2.21 − 3.94) | |
P-value* | 2.86E-16 |
* One-tailed Fisher’s exact test was performed for the higher rate of hypothyroidism for sunitinib compared to sorafenib.